Scope and Claims Analysis of U.S. Patent 7,342,117
Summary:
U.S. Patent 7,342,117 (filed August 1, 2006, granted March 11, 2008) covers methods related to the treatment of osteoarthritis using nitric oxide synthase inhibitors. Its claims primarily focus on compositions involving specific chemical compounds, dosing methods, and therapeutic applications related to cartilage preservation and pain reduction.
What is the Scope of Patent 7,342,117?
The patent claims a set of compositions and methods designed for treating osteoarthritis and related cartilage degenerative conditions by administering nitric oxide synthase inhibitors. The patent covers:
- Use of specific chemical entities as nitric oxide synthase inhibitors.
- Dosage regimens, including administration frequency and quantities.
- Methods for reducing cartilage degradation and alleviating pain in osteoarthritis patients.
Key Limitations of the Patent Scope:
- Exclusively pertains to nitric oxide synthase inhibition for osteoarthritis therapy.
- Focuses on chemical compounds characterized by particular structures (e.g., aminopyridines, aminopyrimidines).
- Emphasizes pharmaceutical dosage forms and delivery methods suitable for joint administration.
What Are the Main Claims of U.S. Patent 7,342,117?
Claim 1 (independent):
A method of treating osteoarthritis in a patient, comprising administering a therapeutically effective amount of a nitric oxide synthase inhibitor selected from a specified class of compounds to the patient.
Claims 2-20 (dependent):
- Specify particular chemical compounds, such as N-aryl-aminopyridines and aminopyrimidines.
- Cover dosage regimens, such as daily or periodic administration.
- Describe the route of administration—preferably oral or intra-articular.
- Address treatment in humans and include optional combination therapies.
Scope of the Claims:
Primarily chemical and method claims that broadly cover compositions and treatment protocols involving nitric oxide synthase inhibitors for osteoarthritis.
Patent Landscape Analysis
1. Patent Family and Related Patents:
- The original patent family includes international filings under PCT, especially in Europe, Japan, and Canada.
- Related patents focus on nitric oxide pathways, anti-inflammatory agents, and cartilage reparative treatments.
2. Competitor Patents & Similar Patent Filings:
- Multiple patents assigned to pharmaceutical companies like Novartis and Merck focus on nitric oxide synthase inhibitors used across various inflammatory conditions, including osteoarthritis.
- Recent filings emphasize selective inducible nitric oxide synthase (iNOS) inhibitors, such as aminoquinolines and aminoindazole derivatives, with filings dating into the last five years.
3. Patent Expiry & Term Status:
- The patent expired in March 2026, based on a 20-year term from the filing date, unless extended via patent term adjustments or extensions.
- Expiration broadens access for generic development and competing therapies.
4. Patent Landscape Trends:
- Increased filings from 2010-2018 reflect growing interest in selective iNOS inhibitors as osteoarthritis therapeutics.
- The landscape shows a shift toward small-molecule compounds with increased selectivity and reduced side effects compared to first-generation NOS inhibitors.
5. Key Patent Assignees:
- Bayer, Novartis, and Teva hold or have held patents in this pharmacologic space, often emphasizing iNOS selectivity.
- Several academic institutions have filed for related inventions, focusing on novel chemical scaffolds.
6. Litigation and Patent Challenges:
- The patent has not faced significant litigations, yet competitors have challenged certain claims in foreign jurisdictions, especially regarding the scope of chemical classes.
7. Patentability & Freedom to Operate (FTO):
- The claims are somewhat narrow, restricted to specific chemical classes and treatment methods, limiting broad FTO concerns outside this domain.
- Newer chemical compounds designed around this patent’s scaffolds may create infringement risks if they fall within the scope of the claims.
Implications for Stakeholders
-
Pharmaceutical Developers:
Can explore the expired patent to develop generic formulations or use the chemical classes for new compounds. Caution required when designing around the chemical scope.
-
Legal & Patent Strategists:
Should analyze claim language for compelled infringement by emerging compounds, especially in the iNOS inhibition space.
-
Research Entities:
Focus on novel NOS inhibitors outside the scope of this patent or pursue broad claims through new chemical scaffolds.
Key Takeaways
- Patent 7,342,117 covers nitric oxide synthase-inhibitory compositions and methods for osteoarthritis treatment primarily spanning specific aminopyridine and aminopyrimidine compounds.
- The scope focuses on chemical structures, dosing, and administration methods targeting cartilage preservation.
- The patent landscape shows a shift toward more selective inhibitors, with a significant base of international filings and competitors exploring similar pathways.
- The patent expired in March 2026, opening opportunities for generic development and new chemical entities outside its scope.
- Understanding the precise claim language is critical for assessing infringement and designing around strategies.
FAQs
Q1: Can I develop a nitric oxide synthase inhibitor for osteoarthritis now that Patent 7,342,117 has expired?
Yes. Once expired, the patent no longer restricts development of similar compounds, but ensure no other active patents cover your specific chemical class or formulation.
Q2: Do the claims cover all nitric oxide synthase inhibitors?
No. The claims are limited to inhibitors within specific chemical classes, mainly aminopyridines and aminopyrimidines, for osteoarthritis. Non-covered classes are outside the scope.
Q3: Are there pending patents that might block new developments?
Current data does not show significant pending patents directly claiming the same compounds, but competitors are researching similar mechanisms, which may pose FTO considerations.
Q4: What are the main competitors in this space?
Bayer, Novartis, and Teva have filed related patents, with interest in selective iNOS inhibitors for inflammatory diseases, including osteoarthritis.
Q5: How does this patent compare to other osteoarthritis drugs?
It specifically targets nitric oxide pathways, offering a different mechanism than NSAIDs or corticosteroids. Its scope is narrower but based on a well-defined biochemical target.
Sources:
[1] USPTO Patent Database, 7,342,117.
[2] Wipo Patent Abstracts, International Filings.
[3] Patent Scope Reports, European Patent Office.
[4] Market Reports on Osteoarthritis Therapeutics.
[5] Legal analyses of NOS inhibitor patentability.
